Guardant Health (GH) traded lower (down ~3.9% to about $84.56) as the market appeared to lean into a risk-off, profit-taking setup rather than a fresh fundamental catalyst. In the most recent filings window, a director reported an open-market sale (March 6, 2026), adding to “insider overhang” concerns that can pressure high-multiple growth names on down tape days. (corestreet.com)

The selling comes after Guardant highlighted a sizable 2026 outlook and margin improvement targets in recent public commentary, which helped drive earlier strength and left the stock vulnerable to pullbacks when incremental news is light. With expectations elevated around the Shield screening ramp and broader platform growth, traders often react quickly to any perceived demand-vs.-burn tradeoff or valuation concerns. (tipranks.com)

Near-term, investors will likely focus on whether incremental reimbursement and coverage expansion continues to build momentum for Shield and whether management reiterates its 2026 trajectory at upcoming conference appearances. Any additional insider selling, financing headlines, or updated commentary on cash burn could also amplify day-to-day volatility. (investing.com)